XTL Biopharmaceuticals Change in Accounts Payable 2010-2024 | XTLB

XTL Biopharmaceuticals change in accounts payable from 2010 to 2024. Change in accounts payable can be defined as the increase or decrease in trade payables for the given period.

XTL Biopharmaceuticals Change in Accounts Payable 2010-2024 | XTLB

XTL Biopharmaceuticals change in accounts payable from 2010 to 2024. Change in accounts payable can be defined as the increase or decrease in trade payables for the given period.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$70.1B
Zoetis (ZTS)$68.6B
Takeda Pharmaceutical (TAK)$47.3B
Daiichi Sankyo, - (DSNKY)$46.4B
BeOne Medicines - (ONC)$33.9B
Sandoz Group AG (SDZNY)$27.3B
Summit Therapeutics (SMMT)$20B
Merck (MKKGY)$16.3B
Shionogi (SGIOY)$14.6B
United Therapeutics (UTHR)$13.9B
Neurocrine Biosciences (NBIX)$13.6B
Orion OYJ (ORINY)$11.3B
IPSEN (IPSEY)$11.1B
Madrigal Pharmaceuticals (MDGL)$9.4B
Eisai (ESAIY)$9.2B
Corcept Therapeutics (CORT)$7.3B
Grifols, S.A (GRFS)$6.8B
Ionis Pharmaceuticals (IONS)$6.7B
Stevanato Group S.p.A (STVN)$6.6B
Ono Pharmaceutical (OPHLF)$5.7B
Hikma Pharmaceuticals Plc (HKMPF)$5.4B
Soleno Therapeutics (SLNO)$3.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.9B
Crinetics Pharmaceuticals (CRNX)$2.9B
NewAmsterdam Pharma (NAMS)$2.8B
Hypermarcas (HYPMY)$2.8B
Catalyst Pharmaceuticals (CPRX)$2.4B
Centessa Pharmaceuticals (CNTA)$2.2B
Ocular Therapeutix (OCUL)$2.1B
Dyne Therapeutics (DYN)$1.9B